-
Mashup Score: 21
This study showed excellent 12-week LDL cholesterol lowering efficacy and good patient tolerance of an oral PCSK9 inhibitor, NNC0835-0434, similar to an injectable drug. However, the sponsor chose to discontinue further development of NNC0835-0434 due to portfolio considerations.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 21
This study showed excellent 12-week LDL cholesterol lowering efficacy and good patient tolerance of an oral PCSK9 inhibitor, NNC0835-0434, similar to an injectable drug. However, the sponsor chose to discontinue further development of NNC0835-0434 due to portfolio considerations.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 21
This study showed excellent 12-week LDL cholesterol lowering efficacy and good patient tolerance of an oral PCSK9 inhibitor, NNC0835-0434, similar to an injectable drug. However, the sponsor chose to discontinue further development of NNC0835-0434 due to portfolio considerations.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 21
This study showed excellent 12-week LDL cholesterol lowering efficacy and good patient tolerance of an oral PCSK9 inhibitor, NNC0835-0434, similar to an injectable drug. However, the sponsor chose to discontinue further development of NNC0835-0434 due to portfolio considerations.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 21
This study showed excellent 12-week LDL cholesterol lowering efficacy and good patient tolerance of an oral PCSK9 inhibitor, NNC0835-0434, similar to an injectable drug. However, the sponsor chose to discontinue further development of NNC0835-0434 due to portfolio considerations.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
In the March Issue: #PCSK9 inhibition with orally administered NNC0385-0434 in #hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial https://t.co/lr8foqHEPj #LDL #cholesterol